한국어 
日本語 
English 
Background
Mandatory compliance training (GMP, pharmaceutical law, adverse event reporting) is unavoidable in pharma. This company achieved high completion rates during compliance windows, but MAU crashed from ~27% to 11% (-59%) in months with zero new content. Compliance MAU was driven by obligation, not platform value.
Solution
Applied the P3 success condition: always-on content must follow compliance training. Used compliance as the "entry point" to expand into P1 (field skill development). Regularly supplied product training, competitor drug comparisons, and clinical paper summaries. Layered newsletters, product updates, and social boards to create multiple reasons to log in.
Results
P3 data shows companies with always-on content retained 40–60% MAU post-compliance, while those that stopped saw single-digit MAU within 2 months. After launching always-on product training, this company slowed its MAU decline and entered a stabilization phase.
Insight
The true test of P3 comes after mandatory-training season. The pharma industry's persistent product-training demand enables a natural expansion from P3 to P1. The industry MAU comparison shows pharma/medical (n=10) at a median of 38%, matching the observation that "persistent product-training demand and lunchtime learning" are the core drivers.
